Some considerations on cerebral vasospasm.
D000287:Administration, Topical; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000818:Animals; D002415:Cats; D002536:Cerebral Arteries / Q000294:innervation; D002543:Cerebral Hemorrhage / Q000150:complications; D002560:Cerebrovascular Circulation; D000242:Cyclic AMP / Q000008:administration & dosage / Q000627:therapeutic use; D004195:Disease Models, Animal; D004285:Dogs; D000882:Haplorhini; D006801:Humans; D002532:Intracranial Aneurysm / Q000150:complications; D002546:Ischemic Attack, Transient / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D010208:Papaverine / Q000627:therapeutic use; D011453:Prostaglandins / Q000494:pharmacology; D013345:Subarachnoid Hemorrhage / Q000150:complications; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D014666:Vasomotor System / Q000503:physiopathology
D000317:Adrenergic alpha-Antagonists; D011453:Prostaglandins; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D010208:Papaverine; D000242:Cyclic AMP